Last reviewed · How we verify
Xtampza ER (oxycodone)
Xtampza ER is an extended-release formulation of oxycodone that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.
Xtampza ER is an extended-release formulation of oxycodone that binds to opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Moderate to severe chronic pain requiring continuous opioid therapy.
At a glance
| Generic name | Xtampza ER (oxycodone) |
|---|---|
| Sponsor | Ajay Wasan, MD, Msc |
| Drug class | Opioid analgesic |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone is a semi-synthetic opioid agonist that binds primarily to mu (μ) opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and producing analgesic effects. The extended-release (ER) formulation uses a proprietary technology to provide sustained drug delivery over 12 hours, reducing dosing frequency while maintaining consistent pain control. Xtampza ER's formulation is designed to be abuse-resistant, making it difficult to crush, chew, or dissolve for misuse.
Approved indications
- Moderate to severe chronic pain requiring continuous opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Headache
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Effect of CYP2D6 on Perioperative Analgesia of Oxycodone in Elderly Patients
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty (PHASE4)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xtampza ER (oxycodone) CI brief — competitive landscape report
- Xtampza ER (oxycodone) updates RSS · CI watch RSS
- Ajay Wasan, MD, Msc portfolio CI